Navigation Links
ULURU Inc. to Present at the 8th World Biomaterials Congress
Date:5/28/2008

- Invited Oral Presentation by Dr. John St. John - - Three Poster Presentations on the Hydrogel Nanoparticle Technology -

ADDISON, Texas, May 28 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) today announced that at the upcoming 8th World Biomaterials Congress, to be held in Amsterdam from May 28th to June 1, 2008, Dr. John St. John, ULURU's Vice President of Material Science, will give an invited oral presentation along with the presentation of three posters.

The title of the invited oral presentation is "Strategies for Tissue Regeneration in Wound Healing with Controlled Release of Actives from Hydrogel Nanoparticle Wound Dressings". This presentation will be made in the session "Tissue Repair and Regeneration" to be conducted on June 1, 2008.

A poster titled "Control of Vascular Proliferation and Healing in Acute Wounds with Controlled Release of VEGF from Hydrogel Nanoparticle Dressings" will be presented in a session on May 31, 2008. Additionally, two posters will be presented at the "Biomaterials for Plastic Surgery -- Poster Session" on May 31, 2008. The titles of these posters are "Formulation and Preclinical Evaluation of Hydrogel Nanoparticle-Hyaluronic Acid Dermal Fillers" and "Hydrogel Nanoparticle Gels as Breast Implant Filler Materials."

Commenting on the upcoming presentation Dr. John St. John stated "I am very pleased to be an invited speaker at this prestigious Biomaterials Congress. This Congress gives ULURU the opportunity to showcase our hydrogel nanoparticle aggregate technology along with a portion of the extensive body of work that we have accumulated supporting our product developments. Additionally, this is an ideal forum to present a representative part of the extensive data that we have generated on the controlled release of active agents to improve wound healing."

Utilizing the experience we are gaining in the United States, we are planning to roll out the launch of Altrazeal(TM), ULURU's first wound dressing utilizing our nanoparticle aggregate technology, extensively throughout the world in the upcoming 12 months. Activities are ongoing to secure a CE mark designation by year-end 2008 which would enable Altrazeal(TM) to be marketed throughout Europe and other international markets. The initial wound dressing containing an active agent, silver, an anti microbial and anti bacterial agent, has recently completed the necessary GLP toxicology studies and we expect to file for 510k approval with the FDA in the second half of 2008.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management, oral care and plastic surgery products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its Hydrogel Nanoparticle Aggregate technology and innovative transmucosal delivery system. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to our expectation of filing a 510k in the second half of 2008, the expectation of rolling out the launch of Altrazeal(TM) extensively throughout the world in the upcoming 12 months and the expectation of securing of a CE Mark designation by year-end 2008. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007, Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company

Kerry P. Gray

President & CEO

Terry K. Wallberg

Vice President & CFO

(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
2. CryoLife to Present at FBR Capital Markets Annual Spring Investor Conference
3. Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008
4. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
5. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
6. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
7. AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
8. West Pharmaceutical Services to Present at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference
9. Martek to Present at Upcoming UBS Conference
10. eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008
11. Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)...   Boston Biomedical , an industry leader in ... stemness pathways, will feature data from two clinical studies ... ASCO Gastrointestinal Cancers Symposium, held from January 19-21, in ... Napabucasin is an orally-administered investigational agent designed to inhibit ... stem cells (CSCs) possess the property of stemness – ...
(Date:1/18/2017)... Malden, MA (PRWEB) , ... January 18, 2017 ... ... announced today that Dr. Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation ... Medical Center in Valley Stream, NY. The procedure was an anterior cervical discectomy ...
(Date:1/18/2017)... ... ... Researchers from a new study are stating that if levels of the blood ... this indicates there is still remaining prostate cancer cells that are more likely to come ... always been an indicator of whether a man’s prostate cancer is growing or not,” ...
(Date:1/18/2017)... ... , ... Thirty-six startup companies in University City and Center City have been ... Economic Development in 2016 as part of the Keystone Innovation Zone (KIZ) Tax Credit ... and represent the highest number of awards to the largest number of companies in ...
Breaking Biology Technology:
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a leading ... the release of its patent-pending calibration device. With this ... perform calibrations, securely upload data logs and process repairs ... customer. "Fighting drunk driving through the application ... public at large, but also for the customer who ...
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
(Date:12/22/2016)... 20, 2016  As part of its longstanding mission to ... genetics company, recently released its latest children,s book, titled ... focuses on the topics of inheritance and variation of traits ... taught in elementary school classrooms in the US. ... illustrator Ariana Killoran , whose previous book with 23andMe, ...
Breaking Biology News(10 mins):